Uemura Y, Pak S C, Luke C, Cataltepe S, Tsu C, Schick C, Kamachi Y, Pomeroy S L, Perlmutter D H, Silverman G A
Division of Newborn Medicine, Department of Pediatrics, Harvard Medical School, Children's Hospital, Boston, MA 02115-5737, USA.
Int J Cancer. 2000 Jul 20;89(4):368-77. doi: 10.1002/1097-0215(20000720)89:4<368::aid-ijc9>3.0.co;2-6.
An elevation in the circulating level of the squamous-cell carcinoma antigen (SCCA) can be a poor prognostic indicator in certain types of squamous-cell cancers. Total SCCA in the circulation comprises 2 nearly identical, approximately 45 kDa proteins, SCCA1 and SCCA2. Both proteins are members of the high-molecular weight serine proteinase inhibitor (serpin) family with SCCA1 paradoxically inhibiting lysosomal cysteine proteinases and SCCA2 inhibiting chymotrypsin-like serine proteinases. Although SCCA1 and SCCA2 are detected in the cytoplasm of normal squamous epithelial cells, neither serpin is detected normally in the serum. Thus, their presence in the circulation at relatively high concentrations suggests that malignant epithelial cells are re-directing serpin activity to the fluid phase via an active secretory process. Because serpins typically inhibit their targets by binding at 1:1 stoichiometry, a change in the distribution pattern of SCCA1 and SCCA2 (i.e., intracellular to extracellular) could indicate the need of tumor cells to neutralize harmful extracellular proteinases. The purpose of our study was to determine experimentally the fate of SCCA1 and SCCA2 in squamous carcinoma cells. Using subcellular fractionation, SCCA-green fluorescent fusion protein expression and confocal microscopy, SCCA1 and SCCA2 were found exclusively in the cytosol and were not associated with nuclei, mitochondria, lysosomes, microtubules, actin or the Golgi. In contrast to previous reports, metabolic labeling and pulse-chase experiments showed that neither non-stimulated nor TNFalpha/PMA-stimulated squamous carcinoma cells appreciably secreted these ov-serpins into the medium. Collectively, these data suggest that the major site of SCCA1 and SCCA2 inhibitory activity remains within the cytosol and that their presence in the sera of patients with advanced squamous-cell carcinomas may be due to their passive release into the circulation.
在某些类型的鳞状细胞癌中,循环水平的鳞状细胞癌抗原(SCCA)升高可能是预后不良的指标。循环中的总SCCA由2种几乎相同、分子量约为45 kDa的蛋白质SCCA1和SCCA2组成。这两种蛋白质都是高分子量丝氨酸蛋白酶抑制剂(丝氨酸蛋白酶抑制剂)家族的成员,SCCA1反常地抑制溶酶体半胱氨酸蛋白酶,而SCCA2抑制胰凝乳蛋白酶样丝氨酸蛋白酶。尽管在正常鳞状上皮细胞的细胞质中可检测到SCCA1和SCCA2,但在血清中通常检测不到这两种丝氨酸蛋白酶抑制剂。因此,它们以相对较高的浓度存在于循环中表明恶性上皮细胞正通过活跃的分泌过程将丝氨酸蛋白酶抑制剂的活性重新导向液相。由于丝氨酸蛋白酶抑制剂通常以1:1的化学计量比结合来抑制其靶标,SCCA1和SCCA2分布模式的改变(即从细胞内到细胞外)可能表明肿瘤细胞需要中和有害的细胞外蛋白酶。我们研究的目的是通过实验确定SCCA1和SCCA2在鳞状癌细胞中的去向。使用亚细胞分级分离、SCCA-绿色荧光融合蛋白表达和共聚焦显微镜检查,发现SCCA1和SCCA2仅存在于细胞质中,与细胞核、线粒体、溶酶体、微管、肌动蛋白或高尔基体无关。与先前的报道相反,代谢标记和脉冲追踪实验表明,无论是未刺激的还是经肿瘤坏死因子α/佛波酯刺激的鳞状癌细胞都没有明显地将这些卵清蛋白丝氨酸蛋白酶抑制剂分泌到培养基中。总体而言,这些数据表明SCCA1和SCCA2抑制活性的主要部位仍在细胞质中,它们在晚期鳞状细胞癌患者血清中的存在可能是由于它们被动释放到循环中。